Supernus to Acquire Adamas Pharmaceuticals in $400 Million Deal

Supernus will acquire Adamas’ Parkinson's disease treatment portfolio through a $400 million acquisition.

Supernus Pharmaceuticals, a biopharmaceutical company focused on conditions targeting the central nervous system (CNS), announced on Oct. 11, 2021, that it would acquire Adamas Pharmaceuticals, a pharmaceutical company focusing on neurological therapies, for approximately $400 million dollars. The acquisition is expected to close late in the 2021 fourth quarter or early in the 2022 first quarter.

Under the agreement, Supernus will purchase shares of Adamas at $8.10 per share. An additional $1.00 per share, equivalent to approximately $50 million, will be paid contingent on Gocovri hitting particular sales milestones. Through this acquisition, Supernus will gain the rights to Adamas’ Gocovri (amantadine) and Osmolex (amantadine) extended-release capsules.

According to a Supernus press release, Gocovri is the first and only FDA-approved medicine for the treatment of both dyskinesia and “off periods” in patients with Parkin’s disease receiving levodopa-based therapy. Osmolex is approved for the treatment of Parkinson’s disease and drug-induced extrapyramidal reactions in adult patients.

“This acquisition represents a significant step to further build a strong and diverse Parkinson’s disease portfolio and aligns with our focus of acquiring value-enhancing, clinically-differentiated medicines to treat CNS diseases,” said Jack Khattar, president and CEO of Supernus Pharmaceuticals, in the press release. “We have a proven track record of strong commercial execution and look forward to building on [Gocovri’s] growth momentum so that more patients can benefit from access to Adamas’ innovative neurological therapies."

Source: Supernus